Vir Biotechnology Inc
NASDAQ:VIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vir Biotechnology Inc
NASDAQ:VIR
|
US |
|
Jay Shree Tea and Industries Ltd
NSE:JAYSREETEA
|
IN |
|
Guaranty Trust Holding Company PLC
LSE:GTCO
|
NG |
|
CMC Metals Ltd
XTSX:CMB
|
CA |
|
Fortitude Gold Corp
OTC:FTCO
|
US |
|
China Jinmao Holdings Group Ltd
HKEX:817
|
HK |
|
Beyond Meat Inc
NASDAQ:BYND
|
US |
|
H
|
Haina Intelligent Equipment International Holdings Ltd
HKEX:1645
|
CN |
|
A
|
Ageas SA
LSE:0Q99
|
BE |
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
S
|
Suzhou West Deane New Power Electric Co Ltd
SSE:603312
|
CN |
|
Metallurgical Corporation of China Ltd
SSE:601618
|
CN |
|
Y
|
Yuexiu Transport infrastructure Ltd
HKEX:1052
|
HK |
|
W
|
Ways Electron Co Ltd
SSE:605218
|
CN |
|
Tesson Holdings Ltd
HKEX:1201
|
HK |
|
Mavi Giyim Sanayi ve Ticaret AS
IST:MAVI.E
|
TR |
|
Batulicin Nusantara Maritim Tbk PT
IDX:BESS
|
ID |
Vir Biotechnology Inc
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 444 full-time employees. The company went IPO on 2019-10-11. The company has assembled four technology platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA), through internal development, collaborations, and acquisitions. The firm's pipeline consists of sotrovimab and other product candidates targeting COVID-19, hepatitis B virus (HBV), influenza A virus, and human immunodeficiency virus (HIV). Its product candidates include Sotrovimab and VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111. The company is engaged in developing differentiated monoclonal antibodies (mAbs) as well as vaccines and small molecules that focuses is on treating and preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-2218 and VIR-3434, are for the treatment of HBV. VIR-2482 is an investigational IM administered influenza A-neutralizing mAb.
Strategic Partnership: Vir announced a major global collaboration with Astellas to co-develop and co-commercialize VIR-5500 for prostate cancer, with up to $1.7 billion in upfront and milestone payments.
Positive Phase I Data: VIR-5500 Phase I results showed strong safety and efficacy, with deep and durable PSA responses, and minimal high-grade cytokine release syndrome, even in heavily pretreated patients.
Reduced Costs: Vir reported a 10% reduction in R&D expenses and a 23% reduction in SG&A for 2025 compared to 2024, reflecting ongoing cost discipline.
Financial Strength: Vir ended 2025 with approximately $782 million in cash and expects its cash runway to extend into the second quarter of 2028.
Pipeline Expansion: The Astellas deal enables Vir to accelerate other programs in its PRO-XTEN platform, with 7 preclinical T cell engagers advancing toward candidate selection.
